- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04738838
Oxytocin on Cold Water Task Performance and Recovery
Evaluating Potential Benefits of Intranasal Oxytocin on Undersea Operator Training and Performance: Cold Water Task Performance and Recovery
Naval Special Warfare (NSW) operators are exposed to a variety of extreme environmental conditions and intense physical demands. In addition to breathing high pressure gases at depth, prolonged cold water immersion and inadequate recovery from sustained physical exertion negatively impact individual and team performance. Biotechnologies that could mitigate the effects of cold as well as support physical recovery represent a significant unmet need for the NSW operational community.
Oxytocin (OT) has a wide range of actions both locally in the brain and peripherally in the body including skeletal muscle. These peripheral effects can be mediated by classic ligand-receptor activation given the abundant expression of the oxytocin receptor in peripheral tissues, along with local expression of OT in peripheral tissues where it is likely to act in an autocrine manner. Exogenous OT via intranasal administration is FDA Investigational New Drug (IND)-approved and has been demonstrated as an easy and safe method to increase circulating OT concentrations that may augment actions on peripheral tissues.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Naval Special Warfare (NSW) operators are exposed to a variety of extreme environmental conditions and intense physical demands. In addition to breathing high pressure gases at depth, prolonged cold water immersion and inadequate recovery from sustained physical exertion negatively impact individual and team performance. Biotechnologies that could mitigate the effects of cold as well as support physical recovery represent a significant unmet need for the NSW operational community.
Oxytocin (OT) has a wide range of actions both locally in the brain and peripherally in the body including skeletal muscle. These peripheral effects can be mediated by classic ligand-receptor activation given the abundant expression of the oxytocin receptor in peripheral tissues, along with local expression of OT in peripheral tissues where it is likely to act in an autocrine manner. Exogenous OT via intranasal administration is FDA Investigational New Drug (IND)-approved and has been demonstrated as an easy and safe method to increase circulating OT concentrations that may augment actions on peripheral tissues.
Cold water operators undergo an extensive and unique set of physical, physiological, and psychological stressors during a mission. In-water transit may exceed 6 hours submerged in cold water, on rebreathers, and in a confined space. During this lengthy transit, operators must maintain vigilance over navigation, vehicle, and life support controls while exposed to the risks of mixed gas or oxygen rebreather diving, alongside hypothermia, dehydration, undernutrition, and other factors that can significantly degrade operator performance. Once the team has reached target, they must be at peak cognitive and physical readiness as they carry out their mission objective. When the mission objective is complete, the operators undertake the lengthy return trip back to their deployed base. Optimized operator cognitive and physical performance is essential throughout all phases of a cold water mission, and safe and tolerable approach to optimizing warfighter performance and resilience will be key for future cold water operations.
Given the potential thermogenic and recovery effects or intranasal OT, we hypothesize that prophylactic OT administration, compared to placebo, will mitigate deficits in mission-relevant performance during and after cold water exposure. For this project we will utilize the ONR Cold Water Performance Task Battery, which was designed based on results from a task analysis combined with input from the cold water operator community. The task battery has been validated for its ability to induce changes in core and peripheral body temperature, manual dexterity, cognitive performance, and physical performance following cold water exposure. Our hypothesis will be tested via one specific aim enrolling N=24 18-39 y/o men by using a rigorous, double-blind, placebo- controlled, within-subjects randomized cross-over trial comparing 48 IU OT vs placebo (saline) in cold water performance and recovery.
Specific Aim 1. To investigate the impact of intranasal OT on cold water task performance and recovery using the ONR Cold Water Performance Task Battery, which includes cold water exposure; cognitive performance testing via oculometric assessment and the Defense Automated Neurobehavioral Assessment (DANA); and physical performance testing via a simulated ruck, ladder climb, and manual dexterity testing.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Todd Norell
- Phone Number: 850-202-4405
- Email: tnorell@ihmc.org
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32611
- University of Florida
-
Contact:
- Natalie Ebner, Ph.D.
- Phone Number: 203-691-0371
- Email: Natalie.ebner@ufl.edu
-
Pensacola, Florida, United States, 32502
- Florida Institute for Human and Machine Cognition
-
Contact:
- Andrew Raines
- Phone Number: 850-202-4414
- Email: araines@ihmc.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Recreationally skilled swimmers
Exclusion Criteria:
- Smoking/vaping, a history of psychiatric disorders, safety requirements related to the oxytocin administration [hypersensitivity to oxytocin or vasopressin, history of hyponatremia, syndrome of inappropriate antidiuretic hormone secretion, or psychogenic polydipsia, on vasoconstrictors such as desmopressin, pseudoephedrine, or antidiuretic medication, or anti-inflammatory drugs, or muscle relaxants, low sodium and high osmolality levels, excessive smoking, excessive drinking, and significant nasal pathology.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Oxytocin Nasal Spray
Single dose of intranasal oxytocin (48 IU) prior to testing protocol.
|
Intranasal treatment with oxytocin via nasal spray (48 IU per dose)
Other Names:
|
Placebo Comparator: Placebo Nasal Spray
Single dose of intranasal treatment with placebo (identical to oxytocin nose spray minus the oxytocin)
|
Intranasal treatment with placebo via nasal spray
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cognitive performance assessment score change (code substitution)
Time Frame: Within 3 hours post-treatment
|
Changes in code substitution scores as measured by the Defense Automated Neurobehavioral Assessment (DANA).
Data will be measured in milliseconds for response time.
|
Within 3 hours post-treatment
|
Cognitive performance assessment score change (code substitution)
Time Frame: Within 3 hours post-treatment
|
Changes in code substitution scores as measured by the Defense Automated Neurobehavioral Assessment (DANA).
Data will be measured in number of correct or incorrect responses.
|
Within 3 hours post-treatment
|
Cognitive performance assessment score change (reaction time)
Time Frame: Within 3 hours post-treatment
|
Changes in choice reaction time scores as measured by the Defense Automated Neurobehavioral Assessment (DANA).
Data will be measured in milliseconds for response time.
|
Within 3 hours post-treatment
|
Cognitive performance assessment score change (reaction time)
Time Frame: Within 3 hours post-treatment
|
Changes in choice reaction time scores as measured by the Defense Automated Neurobehavioral Assessment (DANA).
Data will be measured in number of correct or incorrect responses.
|
Within 3 hours post-treatment
|
Oculometric assessment score change (saccades)
Time Frame: Within 3 hours post-treatment
|
Altered ocular response as measured by the I-Portal Portable Assessment System (i-PAS).
Saccades will be monitored and counted throughout the duration of the assessment.
|
Within 3 hours post-treatment
|
Oculometric assessment score change (blink rate)
Time Frame: Within 3 hours post-treatment
|
Altered ocular response as measured by the I-Portal Portable Assessment System (i-PAS).
Number of blinks will be counted through the course of the assessment.
|
Within 3 hours post-treatment
|
Oculometric assessment score change (blink duration)
Time Frame: Within 3 hours post-treatment
|
Altered ocular response in blink duration as measured by the I-Portal Portable Assessment System (i-PAS).
Blink duration will be measured in milliseconds.
|
Within 3 hours post-treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduced rating of perceived exertion (RPE) during physical assessment post-cold water exposure
Time Frame: Within 3 hours post-treatment
|
Participants will signal on the Borg (6-20) scale for whole body and lower body exertion following their exposure to cold water.
Lower on the scale signal a lower level of perceived physical exertion.
|
Within 3 hours post-treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in grip strength in cold water
Time Frame: Within 3 hours post-treatment
|
During and after cold water exposure, participants will complete a grip strength assessment through the use of a hand dynamometer.
Measurements will be taken in Newtons.
|
Within 3 hours post-treatment
|
Difference in manual dexterity (underwater knot untying) in cold water
Time Frame: Within 3 hours post-treatment
|
During and after cold water exposure, participants will complete a timed underwater knot untying and peg board time trial.
Measurement will be recorded in seconds.
|
Within 3 hours post-treatment
|
Difference in manual dexterity (underwater peg board assessment) in cold water
Time Frame: Within 3 hours post-treatment
|
During and after cold water exposure, participants will complete a timed underwater peg board assessment time trial.
Measurement will be recorded in seconds.
|
Within 3 hours post-treatment
|
Collaborators and Investigators
Investigators
- Principal Investigator: Marcas Bamman, Ph.D., Florida Institute for Human and Machine Cognition
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-2020-0002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cold Exposure
-
United States Army Research Institute of Environmental...RecruitingCold ExposureUnited States
-
Indiana UniversityRecruitingCold ExposureUnited States
-
University School of Physical Education, Krakow...Active, not recruiting
-
Maastricht UniversityCompleted
-
Direction Centrale du Service de Santé des ArméesRecruitingEating Habit | Cold Exposure | HeatFrance
-
United States Army Research Institute of Environmental...RecruitingGut Microbiome | Cold Exposure | Manual DexterityUnited States
-
Universidade Federal do PiauíCompleted
-
University of BernCompletedHealthy | Stress | Blood Pressure | Cold ExposureSwitzerland
-
University School of Physical Education, Krakow...RecruitingCold Exposure | Heat Exposure | Hypoxia, AltitudePoland
-
Lithuanian Sports UniversityCompletedFasting | Cold Exposure | Calorie DeficiencyLithuania
Clinical Trials on Oxytocin nasal spray
-
Sara EspinozaThe University of Texas Health Science Center, Houston; The University of Texas... and other collaboratorsCompletedObesity | Sedentary Lifestyle | Sarcopenia | Aging | Sarcopenic ObesityUnited States
-
University Hospital, ToulouseCompletedPrader-Willi SyndromeFrance
-
University of Electronic Science and Technology...Completed
-
Massachusetts General HospitalCompleted
-
University of Sao Paulo General HospitalTerminated
-
Florida Institute for Human and Machine CognitionUniversity of Alabama at Birmingham; University of Florida; Translational Genomics... and other collaboratorsCompleted
-
University of North Carolina, Chapel HillCompletedSchizophrenia | Schizoaffective Disorder | ParanoiaUnited States
-
Rambam Health Care CampusCompletedPost Traumatic Stress DisorderIsrael
-
Stanford UniversityCompleted
-
King's College LondonFather Flanagan's Boys' HomeCompletedAntisocial Personality DisorderUnited Kingdom